On November 16, 2026, Clover Health Investments, Corp. (the “Company”) published a list of responses to a selection of frequently asked supplemental questions submitted in connection with the Company's third quarter 2026 earnings announcement in order to further engagement with the Company's shareholder base. The supplemental questions and the Company's accompanying written responses are furnished as Exhibit 99.1 to this Current Report on Form 8-K, and are also available on the investor relations section of the Company's website.
|
Clover Health Investments, Corp. is a healthcare company that operates Medicare Advantage plans and provides technology-enabled care management services. The company offers Preferred Provider Organization (PPO) and Health Maintenance Organization (HMO) plans to Medicare beneficiaries, focusing on wide physician networks and low out-of-pocket costs. Its core technology, Clover Assistant, is a cloud-based software platform that uses machine learning and artificial intelligence to provide physicians with real-time, data-driven insights for chronic disease management. Clover Health also operates Clover Home Care, a longitudinal home-based primary care program for high-acuity members, and Counterpart Health, a subsidiary that licenses the Clover Assistant platform externally to other payors and providers as a Software-as-a-Service solution. The company serves Medicare-eligible seniors in the United States, specifically operating in five states and numerous counties, with a focus on underserved markets and patients with chronic conditions. Summarised from the company's own disclosures, fiscal year ended Feb 2026 |
Industry Healthcare Plans | Homepage cloverhealth.com |
| Sector Healthcare | IR page investors.cloverhealth.com | |
|
Tags
medicare advantage, chronic disease management, clinical decision support, home-based primary care, healthcare software, pso plans, hmo plans, ai-powered care management, Clover Assistant, Counterpart Assistant, Clover Home Care, Counterpart Health Inc.
|
Press page — |
Metrics
| Valuation | |
|---|---|
| Market cap | $ 2.771B |
| Market cap (USD) | $ 2.771B |
| P/E | 222.54 |
| PEG | — |
| P/BV | 7.09 |
| P/S | 1.01 |
| P/OCF | 20.48 |
| P/FCF | 20.95 |
| Dividend yield | — |
| Turnover / mcap | — |
| Returns | |
|---|---|
| ROE | -26.3% |
| ROI | -27.7% |
| ROIC | -20.8% |
| Profit margin | -4.4% |
| Growth | |
|---|---|
| Revenue growing | No |
| Profits growing | No |
| Revenue up 3y | No |
| Revenue up 5y | — |
| Earnings growth 3y (net profit CAGR) | — |
| Quality | |
|---|---|
| Profitable | No |
| Margin expanding | No |
| Buying back stock | No |
| Diluting (TTM) | Yes |
| Debt/Equity | — |
| Podcast bulls (TTM) | Sign up |
| Podcast bears (TTM) | Sign up |
| Podcast sentiment (TTM) | Sign up |
| Podcast sentiment % (TTM) | Sign up |
| News sentiment (TTM) | 42 |
| Quality score | -81.3% |
| Insiders | |
|---|---|
| Buys, 1w | Sign up |
| Buys, 1m | Sign up |
| Buys, 1y | Sign up |
| Sells, 1w | Sign up |
| Sells, 1m | Sign up |
| Sells, 1y | Sign up |
Sign up to see this company's insider trades
Filed figures
Lines the statements and their notes report beside the headline figures, read from the filings' XBRL as filed (no restatement applied), with figures computed from one filing's own lines. Cash-flow lines carry their cash direction: an outflow is negative. Each period links to its filing; a figure's period, report date and tag are in its tooltip.
| Figure | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Balance sheet detail | ||||||||
| Borrowings, current (USD) | — | — | 20.8M | 0.00 | — | — | — | — |
| Borrowings, non-current (USD) | — | — | 106M | 19.9M | 0.00 | — | — | — |
| Lease liabilities (USD) | — | — | 4.8M | 7.89M | 5.86M | 4.66M | 3.33M | 3.3M |
| Cash and deposits (USD) | 75.4M | 0.00 | 28M | 300M | 104M | 123M | 195M | 78.3M |
| Right-of-use assets (USD) | — | — | 7.88M | 5.37M | 4.03M | 3.38M | — | — |
| Net debt (borrowings + leases - cash) (USD) | — | — | 18.9M | -272M | -97.9M | — | — | — |
| Cash flow detail | ||||||||
| Operating cash flow (USD) | — | -160M | -2.23M | -282M | -204M | -116M | 34.8M | -66.9M |
| Purchases of property, plant and equipment (USD) | — | -23,000 | -693,000 | -723,000 | -4.47M | -584,000 | -1.56M | -2.04M |
| Change in receivables (cash effect) (USD) | — | -14.5M | -12.9M | -9.3M | -22.6M | 6.44M | 12.6M | -43.3M |
| Change in payables (cash effect) (USD) | — | 6.3M | 10.8M | 5.31M | 7.64M | 4.74M | -2.62M | 1.65M |
| Share buybacks (cash effect) (USD) | — | 0.00 | 0.00 | -147,000 | -6.36M | -6.22M | -1.77M | -18.3M |
| Interest paid (cash effect) (USD) | — | -6.26M | -4.58M | -1.68M | 0.00 | 0.00 | — | — |
| Income taxes paid (cash effect) (USD) | — | — | — | — | — | — | — | 0.00 |
| Share-based compensation (USD) | — | 3.3M | 7.08M | 164M | 164M | 141M | 114M | 104M |
| Operating cash flow before change in receivables (USD) | — | -145M | -106M | -273M | -181M | -122M | 22.2M | -23.6M |
| Free cash flow (OCF - PPE - intangibles) (USD) | — | -160M | -119M | -283M | -208M | -116M | 33.3M | -69M |
| Income detail | ||||||||
| Total comprehensive income (USD) | — | -364M | -136M | -590M | -346M | -206M | -42.2M | -83.4M |
| Comprehensive income to owners (USD) | — | -364M | -136M | -590M | -346M | -206M | -42.2M | -83.4M |
| Reported | Feb 28, 2022 | Feb 28, 2022 | Feb 28, 2022 | Feb 28, 2022 | Mar 1, 2023 | Mar 14, 2024 | Mar 3, 2025 | Feb 27, 2026 |
Sign up to see institutional holdings
Sign UpPodcast Mentions
Sign up to see podcast mentions and sentiment
Sign UpMaterial events reported to the SEC on Form 8-K or 6-K, newest first. The link opens the filing itself on EDGAR. Press releases from the company's own website, newest first.
Business Highlights:
•Strong third quarter performance brings year-to-date GAAP Net Income to $62 million alongside 49% year-over-year Medicare Advantage membership growth
•Improved Full Year 2026 guidance across all metrics
•2027 AEP tracking well, with significant growth due to strong product positioning in core markets
•Clover’s flagship PPO, representing ~98% of current membership, received a 5 Star rating for Payment Year 2028
Financial Results:
•Third quarter 2026 GAAP Net Income of $6 million, an improvement of $31 million year-over-year
•Third quarter 2026 Medicare Advantage membership of 158,907, up 45% year-over-year, and Total revenues of $759 million, up 53% year-over-year
•Third quarter 2026 Consolidated Gross Profit of $130 million, up 77% year-over-year, and Adjusted EBITDA of $16 million, up $14 million year-over-year
Improved Full Year 2026 Guidance:
•Average Medicare Advantage membership of 157,000 - 158,000, representing 47% growth year-over-year at the midpoint
•Total revenues between $2.97 billion and $3.00 billion, representing 55% growth year-over-year at the midpoint
•GAAP Net Income between $25 million and $35 million
•Consolidated Gross Profit
October 26, 2026
WILMINGTON, Del., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), today announced that its Interim Chief Financial Officer, Clay Thornton, will present at the 2026 UBS Global Healthcare Conference on Monday, November 9, 2026, at 12:30 p.m. Eastern Time.
A live webcast and replay of the presentation and Q&A session will be accessible on Clover Health's investor relations website at https://investors.cloverhealth.com/.
About Clover Health: Clover Health (Nasdaq: CLOV) is a physician enablement technology company committed to bringing access to great healthcare to everyone on Medicare. This includes a focus on seniors who have historically lacked access to affordable, high-quality healthcare. Our strategy is powered by our software platform, Clover Assistant, which is designed to aggregate patient data from across the healthcare ecosystem to support clinical decision-making and improve health outcomes through the early identification and management of chronic disease. For our members, we provide PPO and HMO Medicare Advantage plans in several states, with a differentiated focus on our flagship wide-network, high-choice PPO plans. For healthcare providers outside Clover Health's Medicare Advantage plan, we extend the benefits of our data-driven technology platform to a wider audience via our subsidiary, Counterpart Health, and aim to enable enhanced patient outcomes and reduced healthcare costs on a nationwide scale. Clover Health has published data demonstrating the technology’s impact on Medication Adherence, Congestive Heart Failure, Chronic Obstructive Pulmonary Disease, and in Underserved Populations as well as the earlier identification and management of Diabetes and Chronic Kidney Disease.
Investor Relations: Ryan Schmidt [email protected]
Press Inquiries: [email protected]

Search Investor Relations
×
Prompts
Click prompts to add them under the company line, click again to take one out, then copy the result into your AI chat. Shared by Asian Century Stocks and Uncovered Thai Stocks. Thank you.
Company History
Name and ticker changes, and re-registrations under a new regulatory id. When a ticker stopped being used is not recorded, so former tickers are undated.
| Date | Change | Detail |
|---|---|---|
| Nov 17, 2020 | Renamed | SOCIAL CAPITAL HEDOSOPHIA HOLDINGS CORP. III → CLOVER HEALTH INVESTMENTS, CORP. /DE |
ETFs Holding Clover Health Investments, Corp.
Exchange-traded funds whose newest published daily portfolio holds one of the company's listings, largest weight first.
| ETF | Weight in ETF | Shares | Market value | As of |
|---|---|---|---|---|
| HYP | 2.78% | 366,103 | $ 1.918M | Jun 30, 2026 |
| SYZ | 0.78% | 101,994 | $ 534.449K | Jun 30, 2026 |
| RESM | 0.10% | 694 | $ 3,636.56 | Jun 30, 2026 |
| VFMO | 0.07% | 333,347 | $ 1.383M | Aug 31, 2026 |
| AVIE | 0.05% | 1,595 | $ 7,895.25 | Nov 16, 2026 |
| VFMF | 0.05% | 116,247 | $ 482.425K | Aug 31, 2026 |
| DFAS | 0.02% | 1,434,676 | $ 7.001M | Nov 12, 2026 |
| MSSM | 0.01% | 25,513 | $ 105.879K | Aug 31, 2026 |
| DXUV | 0.01% | 110,536 | $ 539.416K | Nov 12, 2026 |
| DFSU | 0.01% | 37,041 | $ 180.76K | Nov 12, 2026 |
| DFUS | 0.00% | 143,928 | $ 702.369K | Nov 12, 2026 |
| DFAC | 0.00% | 460,446 | $ 2.247M | Nov 12, 2026 |
| DCOR | 0.00% | 224,826 | $ 1.097M | Nov 12, 2026 |
| DFAU | 0.00% | 10,570 | $ 51.582K | Nov 12, 2026 |
| AVUS | 0.00% | 4,132 | $ 20.453K | Nov 16, 2026 |
| AVSC | 0.00% | 10,690 | $ 52.916K | Nov 16, 2026 |



















